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Abstract
Objectives—Nitric oxide (NO) is a reactive gas generated by inflammatory cells and mucosal
epithelial cells of the nose and paranasal sinuses and is an important mediator in nonspecific host
defense against infectious agents. However, NO also mediates physiologic events such as
vasodilation, mucus hypersecretion, and mucosal disruption that are associated with inflammatory
conditions, and it is a regulator of ciliary beat frequency. In the present study, we hypothesized
that lifestyle exposure to tobacco smoke, whether through active smoking or by inadvertent
exposure to secondhand tobacco smoke, would result in higher detectable levels of nasal NO
(nNO) than are found in well-documented nonsmokers.
Methods—Nasal NO measurements were obtained concomitant with assays of urine cotinine
from well-documented nonsmokers, active smokers, and individuals exposed by lifestyle to
secondhand smoke. These parameters were statistically analyzed to determine whether increasing
levels of tobacco smoke exposure yield higher concentrations of nNO.
Results—Our results and subsequent statistical analyses imply that active smokers who exhibit
high urine cotinine levels exhibit significant increases in nNO levels in comparison to both
nonsmokers and nonsmokers exposed to secondhand smoke.
Conclusions—There is an increased level of nNO associated with tobacco smoke exposure that
may contribute to the inflammatory processes characteristic of disease pathogenesis in smokers.
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INTRODUCTION
Since the discovery of its function as the endothelium-derived relaxing factor,1 nitric oxide
(NO) has been further documented to be an important physiologic signaling molecule, to
have proinflammatory properties, and to undergo detectable modifications of concentration
in certain pathologic conditions. The development of sensitive techniques for instantaneous
measurement and monitoring of NO concentration in human airways spurred many clinical
studies in which NO excretion into the nasal and lower airways was related to a variety of
diseases, as well as to therapeutic interventions. These discoveries have led to speculation on
the potential of NO as a biomarker of health and disease. For example, extensive studies
have strongly suggested that NO flux measurements may have potential clinical utility in the
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management of asthma2,3 or as a potential diagnostic marker of rare airway diseases such as
cystic fibrosis4 and primary ciliary dyskinesia.5
The NO in the airways is synthesized from L-arginine and oxygen by three nitric oxide
synthase (NOS) isoforms.6–8 Although airway epithelial cells clearly express NOS, produce
NO, and are believed to be the major source of lower airway NO, it is less clear which NOS
isoforms are expressed under conditions of normal function or disease at different levels of
the airways. There exists a particular deficit of information regarding nasal NO (nNO) levels
and tobacco smoke exposure. Thus, the lack of a clear understanding of the relationship
between NO excreted into the airway lumen, total NO production, and the role of the
constitutive NOS isoforms in different pathologic states has reduced the ability to interpret
the quantitative data provided by this emergent noninvasive marker of airway disease. In the
present study, we assessed nNO levels among human subjects with a variety of lifestyle
tobacco smoke exposure histories and correlated them with urine cotinine values.
METHODS
Human Subjects
This study was reviewed and approved by The University of North Carolina at Chapel Hill
Office of Human Research Ethics. A total of 88 subjects with a broad range of smoking
histories were recruited. At the time of recruitment, all of the subjects, regardless of smoking
history, reported subjectively that their overall health was good. Asthma and/or other
previously diagnosed chronic respiratory diseases were exclusion criteria. Participants self-
reported their status upon entering the study as belonging to 1 of 3 groups: 1) ex-smokers
and nonsmokers, 2) current smokers, and 3) nonsmokers who are domestically or
occupationally exposed to secondhand tobacco smoke (NS/SHS). The individuals who
identified themselves as smokers subjectively reported recent cigarette use as no more than 2
packs of cigarettes per day. The subjects also completed a questionnaire assessing their
general health, current respiratory symptoms, and other relevant information that allowed
consideration for exclusion from the study if indicated. There were 35 nonsmokers, 35
smokers, and 18 NS/SHS in the study groups. There were 38 male and 50 female subjects,
and the race distribution was consistent with the population demographics of central North
Carolina. The median ages were 25 years for nonsmokers, 34 years for smokers, and 26
years for NS/SHS.
Nasal Nitric Oxide Assays
The nNO level was measured by use of a Sievers model 280i NOA nitric oxide analyzer
(General Electric Analytical Instruments, Boulder, Colorado) employing a mouth resistor
method.9 The disposable nasal sampling probes and mouth resistors were obtained from
DirectMed, Inc (Glen Cove, New York). The sampling flow rate was 0.5 L/min. The nNO
determination protocol was based on American Thoracic Society/European Respiratory
Society recommendations.9 Briefly, after explanation of the procedure to the subject, a nasal
probe connected to the sampling line and the analyzer was inserted into a nostril. Afterward,
the subject was asked to inhale fully and subsequently exhale slowly through a mouth
resistor. The nNO signal was displayed on a monitor, and once the nNO plateau was reached
and maintained for at least 10 seconds, the acquisition was stopped. The measurement was
repeated until 2 acceptable curves were obtained for each nostril (2 or 3 trials). The nNO
concentration (in parts per billion) for each trial was analyzed over a 3- to 5-second interval
of a plateau section of the curve. Nasal NO concentrations were acquired from each nostril,
and the values for both nostrils were averaged and converted into nNO production in
nanoliters per minute.
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Each study subject provided a urine specimen coordinated with the time of the nasal
sampling to obtain a quantitative measure of tobacco smoke exposure and to validate self-
reported tobacco exposure histories. No further effort was made to subcategorize tobacco
exposure levels in the different groups; rather, each group served to provide a range of
lifestyle exposure levels as a function of the type of exposure. Cotinine analyses were
performed with a commercially available enzyme-linked immunosorbent assay (Bio-Quant,
San Diego, California). Creatinine analyses were performed with a colorimetric assay
(Oxford Biomedical Research, Oxford, Michigan). From these data, a cotinine-creatinine
ratio (CCR) was determined for each subject. Because of the great variability in values
across the spectrum of exposure, the CCR values were converted to log 10 for presentation
purposes.
Statistical Analyses
A simple summary of descriptive statistics of the data is given in Table 1. The graph in Fig
1, fitted with a crude local polynomial fitting (LOESS),10,11 depicts an overall and
unadjusted relationship between nNO level and CCR. To investigate the association between
nNO level and CCR and smoking status, we fitted a linear model in which nNO level was
the outcome variable and CCR and smoking status were the independent variables. We first
fitted an oversaturated model (full model) that included age, gender, CCR, CCR2, smoking
status, and interaction terms between CCR and smoking. We then used the likelihood ratio
method to remove factors that were not statistically significant in the model. We arrived at
the final model that was deemed by data and statistical hypothesis testing to best describe
the relationship. To determine whether the nNO level is related to smoking status,
conditional on the subject’s age, gender, and CCR, the regression analysis is the best
statistical approach to optimally analyze the data. This approach to analysis also
complements the hypothesis relative to the NO physiology in the upper airways,6–8;
inasmuch as NO is produced by both the nasal and paranasal sinus mucosa, as well as by
inflammatory cells, and is a known regulator of ciliary beat frequency (CBF), and it is
plausible that production may be linked to inflammatory agents such as tobacco smoke.
RESULTS
Descriptive statistics (Table 1) of relative nNO and CCR values revealed little evident
difference between nonsmokers and NS/SHS. In contrast, nNO levels were reduced among
smokers relative to nonsmokers and NS/SHS, and there was marked variability in individual
measurements. As expected, the CCR was dramatically higher among smokers than in either
of the nonsmoker groups. An unadjusted association between nNO and CCR values was
identified by local polynomial fitting (LOESS; Fig 1). Figure 1 suggests that there might be
a nonlinear relationship between nNO level and CCR. A rigorous test from our regression
analysis results revealed there was a significant quadratic relationship between CCR and
nNO level (p = 0.008) and that there was a significant smoking group effect, with smokers
as the reference (p = 0.008 for nonsmokers and p = 0.006 for NS/SHS). The final model fit
is presented in Table 2. Age and gender showed no effect on nNO level (p = 0.5 for age and
p = 0.41 for gender). We also found a marginally significant interaction effect (p = 0.06)
between smoking status and CCR (not presented), but this effect may require a larger data
set to confirm. Figure 2 illustrates the final fitted regression model demonstrating that
among smokers, a positive relationship exists between nNO level and CCR, whereas both
nonsmokers and NS/SHS exhibited a comparable flat-to-negative association between nNO
level and CCR (Fig 2). Among smokers exhibiting higher CCR values, the relationship
between an elevated CCR and an increased nNO level was dramatic.
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Tobacco smoke exposure elicits an inflammatory response,12,13 and both the airway
mucosa7 and the inflammatory cells14 contain NOS. Thus, we initially hypothesized that
nNO levels would be elevated uniformly among smoke-exposed individuals relative to
nonsmokers. This, however, was not the case, and instead we observed great variability in
individual measurements of nNO among active smokers and an overall reduction in nNO
level among active smokers relative to nonsmokers and NS/SHS. In addition to an
inflammatory response, smokers may typically exhibit nasal congestion and rhinorrhea,
factors that may be in part responsible for the variability of nNO measurements among
active smokers in this study. Not only may nasal congestion occlude the paranasal sinuses,
an anatomic site of relatively higher NO production, but NO generated from the mucosa,
being highly reactive, may interact with secretions to reduce the nNO level. Conversely, the
excessively high nNO levels that were observed among some subjects may be reflective of
relatively unobstructed airways and tobacco smoke-induced increases in nNO.
Mucociliary clearance is mediated in part by the ability of the airway mucosa to up-regulate
CBF through an NO pathway.15,16 Other studies have suggested that regulation of ciliary
function exhibits both adrenergic and cholinergic components.17–19 Moreover, irritants in
ambient air, including tobacco smoke,20 have been shown to accelerate the CBF, Previous
studies from this laboratory21 demonstrated a generalized up-regulation of CBF among
human subjects caused by active smoking and passive exposure. In vitro investigation of this
phenomenon using an NO-specific fluorescent dye in cultured cells suggested that NO is
generated in airway epithelial cells at a level above background by exposure to cigarette
smoke condensate.
Nitric oxide is highly reactive and is capable of many chemical interactions with cellular
constituents, particularly tyrosine22 — a capability that may account for the reduced level of
nNO among some smokers. Previous studies of smokers and subjects with asthma also have
found reduced exhaled NO levels accompanied by increased numbers of mucus-producing
cells. This situation may produce a rich chemical milieu in the airway surface liquid that
facilitates interactions with NO, thereby reducing its concentration upon excretion.23,24 In
this study, the highest levels of nNO were observed in smokers, who exhibited an 8.6-fold
difference between the maximum and minimum nNO values, in contrast to nonsmokers and
NS/SHS, who exhibited 2.7- and 3.8-fold differences, respectively. This great variability in
nNO measurements among smokers suggests that other factors may mitigate NO interaction
with cellular constituents and secretions among smoking subjects, thereby resulting in
readings of elevated NO levels. Although mucociliary clearance causes a net transport of
secretions out of the airway, it is plausible that accumulation and clearance of the airway
surface liquid exhibits some regional variability that may either limit or promote the
interaction of the airway surface liquid with NO.
The biphasic model suggests that relative to nNO level and CCR, the NO physiology among
smokers differs from that of nonsmokers and NS/SHS. The fact that the study population
consisted of several subpopulations (strata) that behave differently in terms of the nNO-CCR
relationship is best distinguished by the linear regression analysis.
In summary, we have demonstrated an association between increased nNO levels as a
function of active smoking and CCRs measured during the same time interval. This
association is most pronounced at higher CCRs, suggesting that heavy smokers excrete more
NO than light smokers. In contrast, urine cotinine levels of nonsmokers and subjects
exposed by lifestyle to secondhand tobacco smoke exhibited no significant association
between exposure and nasal NO levels. In summary, the cell molecular interactions of NO in
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the upper airways in response to tobacco smoke exposure are likely multifactorial, being on
one hand elevated and contributing to the inflammatory response and regulation of ciliary
function, and being on the other hand limited by interaction with cellular proteins and excess
secretions associated with irritant exposure.
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Unadjusted association between nasal nitric oxide and cotinine-creatinine ratio values via
local polynomial fitting (LOESS). NS/SHS — nonsmoker who is domestically or
occupationally exposed to secondhand tobacco smoke.
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Association between nasal nitric oxide and cotinine-creatinine ratio values based on final
regression model for 30-year-old (mean age) male subject.
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TABLE 1








Nonsmokers 35 303 ± 90 1.06 ± 0.77
NS/SHS 18 304 ± 88 1.34 ± 0.78
Smokers 35 278 ± 136 5.43 ± 1.46
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TABLE 2
Regression analysis results for nNO
Parameter Estimate SE P
Intercept 215.09 64.40 0.001
CCR −33.46 24.64 0.178
CCR2 8.94 3.30 0.008
Age −0.93 1.30 0.477
Gender (female) −20.94 25.02 0.405
NS/SHS 158.01 56.04 0.006
Nonsmokers 146.56 53.66 0.008
Male is reference for gender, and “smokers” is reference for smoking status. Regression model: nNO = α + β1CCR + β2CCR2 + β3Age +
β4I(gender = female) + β5I(smoking = NS/SHS) + β6I(smoking = nonsmokers) + ε, where ε ~ N(0,σ2).
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